Pricing Log in Create free account

Actuate Therapeutics, Inc. (ACTU) vs Pluri Inc. (PLUR)

Actuate Therapeutics, Inc. and Pluri Inc. are both Biotechnology companies. Actuate Therapeutics, Inc. and Pluri Inc. are of similar size ($12.0M and $11.9M). Actuate Therapeutics, Inc. has the higher net margin (0.00% vs −2,344.6%) and the higher return on invested capital (0.00% vs −526.9%). Across the 12 metrics below, Actuate Therapeutics, Inc. leads on 9 and Pluri Inc. on 3.

Valuation

Metric ACTU PLUR Biotechnology median
P/E n/m n/m 8.50
P/S n/m 8.92 9.71
P/B 14.72 n/m 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales n/m 28.99 9.21
Earnings yield (142.62%) (263.44%) (33.15%)
Free cash flow yield (136.22%) (222.94%) (25.50%)

Profitability

Metric ACTU PLUR Biotechnology median
Gross margin — 44.59% 65.16%
Operating margin 0.00% (2,454.53%) 0.00%
Net margin 0.00% (2,344.59%) 0.00%
Free cash flow margin 0.00% (1,988.48%) 0.00%
Return on equity 2,457.65% 260.35% (56.36%)
Return on assets (336.18%) (74.95%) (48.04%)
Return on invested capital 0.00% (526.92%) 0.00%

Growth

Metric ACTU PLUR Biotechnology median
Revenue growth (TTM) — (23.95%) 6.02%
EPS growth (last fiscal year) 67.48% 31.46% 30.26%
Revenue growth, 5-year CAGR — 113.32% 9.41%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric ACTU PLUR Biotechnology median
Debt to equity 0.00 (1.62) 0.00
Current ratio 1.25 0.27 4.72
Net debt to EBITDA 0.59 (0.83) 0.96

Dividend

Metric ACTU PLUR Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric ACTU PLUR Biotechnology median
Market cap 12.01m 11.86m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack